Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Given Average Rating of “Moderate Buy” by Analysts

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.00.

A number of analysts recently commented on the company. Craig Hallum set a $2.00 target price on Alterity Therapeutics in a research report on Tuesday, August 11th. JonesTrading began coverage on Alterity Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $16.00 price objective for the company. Zacks Research upgraded Alterity Therapeutics to a “hold” rating in a report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Friday, July 17th. Finally, UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a research report on Tuesday, August 11th.

Alterity Therapeutics Stock Performance

NASDAQ:ATHE opened at $4.57 on Tuesday. The firm has a fifty day simple moving average of $4.84 and a two-hundred day simple moving average of $4.17. Alterity Therapeutics has a 12 month low of $2.66 and a 12 month high of $5.89.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.